Anemia drug market seen topping $16.8B by 2030

By AI, Created 10:22 AM UTC, May 20, 2026, /AGP/ – The Business Research Company says the global market for anemia and other blood disorder drugs will grow from $12.46 billion in 2025 to $16.88 billion by 2030, driven by personalized medicine, gene therapies and an aging population. North America led in 2025, while the Middle East is projected to post the fastest growth.

Why it matters: - The anemia and blood disorder drug market is expanding as demand rises for more targeted treatments and broader access to hematology care. - The category includes therapies used to treat anemia and other blood diseases, including conditions that trigger hemolysis and premature red blood cell destruction. - The growth outlook points to a larger commercial opportunity for drugmakers focused on rare disorders, specialty clinics and injectable therapies.

What happened: - The Business Research Company released its Global Market Report 2026 on anemia and other blood disorder medications. - The report puts the market at $12.46 billion in 2025 and $13.14 billion in 2026, implying 5.5% annual growth. - The report forecasts the market will reach $16.88 billion by 2030, at a 6.5% CAGR. - North America held the largest share of the market in 2025. - The Middle East is projected to be the fastest-growing region during the forecast period. - Download a free sample of the report. - View the full market report.

The details: - Historical growth has been supported by iron deficiency anemia, chronic kidney disease, blood transfusions, long-term use of erythropoiesis-stimulating agents and established hematology treatment protocols. - Forecast growth is tied to gene therapy adoption, a larger aging population, higher awareness of blood disorders, more specialty hematology clinics and better diagnostics. - The report flags rising chronic blood disorders, greater use of injectable treatments, expanded gene therapy for rare anemias, more personalized hematology care and better access to essential medicines as key trends. - Personalized medicine is a major growth driver because treatment can be tailored to a patient’s genetic profile for more targeted care. - The report says individualized treatment plans are becoming more important as therapies increasingly target specific genetic or molecular features of blood disorders.

Between the lines: - The market forecast suggests treatment innovation is moving from broad anemia management toward precision medicine and rare-disease care. - The regional split shows the category is already mature in North America, while faster adoption may come from markets still building specialty care infrastructure. - The report’s emphasis on gene therapy and injectables signals where product pipelines and reimbursement pressure may concentrate next.

What’s next: - The Business Research Company expects growth to continue through 2030 as diagnostics improve and specialty hematology access widens. - Wider gene therapy use in rare anemias could reshape treatment standards if adoption accelerates. - More personalized care models may continue to influence purchasing and prescribing patterns across the category. - The company also lists related reports on chemotherapy-induced anemia and hematology drugs.